1,25‑dihydroxyvitamin D Defciency Is Independently Associated With Cardiac Valve Calcifcation in Patients With Chronic Kidney Disease

Abstract

Cardiac valve calcification is highly prevalent in patients with chronic kidney disease (CKD). Low vitamin D levels are associated with vascular calcification in CKD. However, the association between vitamin D levels and cardiac valve calcification is unknown. A total of 513 patients with pre-dialysis CKD were included in this cross-sectional study. Aortic valve calcification (AVC) and mitral valve calcification (MVC) were assessed using two-dimensional echocardiography. The associations between AVC and MVC and baseline variables were investigated using logistic regression analyses. In multivariable analysis, serum 1,25(OH)2D level was independently associated with AVC (odds ratio [OR], 0.87; P< 0.001) and MVC (OR, 0.92; P< 0.001). Additionally, age, diabetes, coronary heart disease, calcium×phosphate product, and intact parathyroid hormone levels were independently associated with AVC and MVC. Systolic blood pressure was independently associated with AVC. A receiver-operating characteristic (ROC) curve analysis showed that the best cutoff values of serum 1,25(OH)2D levels for predicting AVC and MVC were≤ 12.5 and≤ 11.9 pg/dl, respectively. Serum 1,25(OH)2D deficiency is independently associated with AVC and MVC in patients with CKD, suggesting that serum 1,25(OH)2D level may be a potential biomarker of AVC and MVC in these patients.

Click here to know what are the Cistanche benefits

Introduction

Cardiovascular disease (CVD) is highly prevalent and the most common cause of death in patients with chronic kidney disease (CKD)1. Cardiac valve calcification is a common complication of CVD and is associated with an increased risk of CVD and all-cause mortality in patients with CKD2–5. The Kidney Disease: Improving Global Outcome (KDIGO) addressed the clinical relevance of cardiac valve calcification in CKD and suggested that cardiac valve calcification should be included in the risk stratification of CVD in patients with CKD6.

Multiple contributors, including traditional factors (age, hypertension, diabetes, and dyslipidemia) as well as non-traditional factors (hyperphosphatemia, calcium phosphate product, and parathyroid function), have been suggested to be involved in cardiac valve calcification in patients with CKD6. Vitamin D plays a central role not only in bone metabolism but also in the vasculature and may be involved in the process of vascular calcifcation7. Indeed, low levels of 25-hydroxyvitamin D [25(OH)D] or 1,25-dihydroxy vitamin D [1,25(OH)2D] have been reported to be associated with coronary artery and cardiac valve calcification in patients with risk factors for CVD and in the general population8–10. Vitamin D metabolism is ubiquitously altered in patients with CKD, and both 1,25(OH)2D and 25(OH)D levels are insufficient in the majority of patients with CKD11. Although an independent association between low levels of 25(OH)D and coronary artery calcification has been previously reported in patients with CKD12,13, whether vitamin D deficiency is associated with cardiac valve calcification in patients with CKD is still unknown.

In this study, we hypothesized that vitamin D deficiency would be independently associated with cardiac valve calcification and investigated the association between serum 1,25(OH)2D levels and aortic valve calcification (AVC) and mitral valve calcification (MVC) in patients with CKD.

Cistanche tubulosa

Methods

Study population. From 2010 to 2019, the data of 513 patients who visited the nephrology clinic at Pusan National University Yangsan Hospital were retrospectively investigated. The estimated glomerular filtration rate (eGFR) was determined using the Modification of Diet in Renal Disease equation: 186×serum creatinine levels−1.154×patient age−0.203×0.742 (if female) or×1.21 (if African-American)14. All enrolled patients were adults (≥18 years old) with CKD (eGFR<60 ml/min/1.73 m2 ) and not on dialysis. To exclude patients with acute kidney injury and to include only patients with CKD, we included only patients whose previous serum creatinine levels were known from medical records or who had been followed for at least three months. We also excluded patients who had taken vitamin D supplements, calcimimetics, or phosphate binders, which could affect the endogenous 1,25(OH)2D metabolism. The study protocol was approved by the Institutional Review Board of Pusan National University Yangsan Hospital (IRB No. 05-2021-119). All research and data collection processes were conducted by the Declaration of Helsinki and current ethical guidelines. The Institutional Review Board of Pusan National University Yangsan Hospital waived the need for informed consent due to the retrospective nature of the analysis, which only used the information available from anonymized medical charts and records.

Data collection. Demographic and clinical data regarding age, sex, current smoking status, history of diabetes, history of CVD (coronary heart disease, cerebrovascular disease, and peripheral vascular disease), history of medication use (angiotensin-converting enzyme inhibitors [ACEI], angiotensin receptor blockers [ARB], calcium channel blockers, beta-blockers, thiazide/loop diuretics, anti-platelet agents, and statins), body mass index (BMI), and blood pressure were obtained by reviewing the medical records, based on our previous report15. Diabetes was defined as the use of diabetes medication, fasting plasma glucose concentration≥126 mg/dl, or A1c hemoglobin levels≥6.5%. Blood pressure was measured from each patient’s upper right arm in a sedentary position using an automated sphygmomanometer after a 5-min rest. BMI was calculated by measuring each patient’s weight and height and was expressed as kg/m2. All serum parameters, including albumin, uric acid, calcium, phosphate, total cholesterol, hemoglobin, C-reactive protein (CRP), intact parathyroid hormone (PTH), and 1,25(OH)2D levels, were measured concomitantly. Serum 1,25(OH)2D levels were measured by a radioimmunoassay (DIAsource ImmunoAssays, Louvain-la-Neuve, Belgium) (reference range 19.6–54.3 pg/ml in healthy adults). The amount of urinary albumin was measured by calculating the urinary albumin-to-creatinine ratio (mg/g Cr).

Echocardiography. Two-dimensional echocardiography was performed using an IE33 echo system (Philips, Amsterdam, Netherlands), based on our previous report16. All echocardiographic data were acquired according to the guidelines of the American Society of Echocardiography17 and were analyzed by an experienced cardiologist who was blinded to the clinical details. The presence of AVC and MVC was determined by visual inspection. Cardiac valve calcification was defined as bright echoes of more than 1 mm in length on one or more cusps of the aortic or mitral valves.

Statistical analysis. Statistical analysis was performed based on our previous report15. Continuous variables are expressed as means±standard deviations, while categorical variables are presented as percentages. Comparisons between the three CKD stage groups or three 1,25(OH)2D tertile groups were performed with a one-way analysis of variance for continuous variables and the chi-square test for categorical variables. Univariate and multivariable logistic regression analyses were used to determine the factors for predicting the presence of AVC, MVC, and at least one valve calcification (AVC or MVC). Significant variables were identified by univariate analysis, and the clinically important variables were selected for multivariable analysis. A receiver-operating characteristic (ROC) curve analysis was performed to assess the area under the curve (AUC) and the Youden index was used to determine the best cutoff value of serum 1,25(OH)2D levels for predicting the presence of AVC, MVC, or at least one valve calcification. Statistical significance was set at P<0.05. All analyses were performed using the SPSS version 26.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc Statistical Sofware version 19.4.1 (MedCalc Sofware, Ostend, Belgium).

Cistanche extract

Discussion

Vascular calcification has received growing attention in patients with CKD, as accumulating evidence suggests that vascular calcification is one of the major causes of CVD in patients with CKD18. However, research has focused on the pathophysiology and clinical impact of vascular calcification as an important part of CKD-MBD, with less attention being paid to cardiac valve calcification in patients with CKD19. However, cardiac valve calcification has been reported to be associated with an increased risk of CVD and death in patients with CKD19. Therefore, verifying the risk factors for cardiac valve calcification is clinically important for improving the prognosis of patients with CKD. In this study, we investigated the associations between various clinical variables and cardiac valve calcification and found that serum 1,25(OH)2D level is an independent risk factor for cardiac valve calcification in patients with CKD.

As the CKD stage increases, cardiac valve calcification is more frequently observed, with the prevalence of AVC increasing from 23% in CKD to 54% in hemodialysis patients, and of MVC, from 25% in CKD to 45% in hemodialysis patients6,19. Consistent with previous reports, our study found that the overall prevalence of AVC was 19.3% (8.5%, 25.4%, and 49.2% in patients with CKD stages 3, 4, and 5, respectively) and that of MVC was 15.8% (7.7%, 19.9%, and 39.3% in patients with CKD stages 3, 4, and 5, respectively) in patients with pre-dialysis CKD. The cardiac valve consists of valve endothelial cells and valvular interstitial cells (VICs). Cardiac valve calcification shares common pathophysiological factors with vascular calcification in patients with CKD. Endothelial dysfunction and calcification of interstitial cells of the valve leaflets are the main pathophysiological features of cardiac valve calcifcation6. The process of cardiac valve calcification is complex, and numerous factors can contribute to its pathogenesis and progression. Advanced age, high blood pressure, genetic factors, mechanical stress, metabolic factors (dyslipidemia, diabetes, metabolic syndrome, and metabolic uremic factors), inflammation, mineral/hormone-related factors (hyperphosphatemia and Ca×P product and PTH levels), and drugs, including calcium-based phosphate binders, have been suggested as risk factors for cardiac valve calcification in patients with CKD6,18–20. Consistent with the findings of previous studies, the multivariable analyses in our study showed that age (for AVC and MVC), systolic blood pressure (for AVC), coronary heart disease (for AVC and MVC), diabetes (for AVC and MVC), and Ca×P product (for AVC and MVC) and intact PTH levels (for AVC and MVC) were independently associated with cardiac valve calcification in patients with CKD.

CKD. The cardiac valve consists of valve endothelial cells and valvular interstitial cells (VICs). Cardiac valve calcification shares common pathophysiological factors with vascular calcification in patients with CKD. Endothelial dysfunction and calcification of interstitial cells of the valve leaflets are the main pathophysiological features of cardiac valve calcifcation6. The process of cardiac valve calcification is complex, and numerous factors can contribute to its pathogenesis and progression. Advanced age, high blood pressure, genetic factors, mechanical stress, metabolic factors (dyslipidemia, diabetes, metabolic syndrome, and metabolic uremic factors), inflammation, mineral/hormone-related factors (hyperphosphatemia and Ca×P product and PTH levels), and drugs, including calcium-based phosphate binders, have been suggested as risk factors for cardiac valve calcification in patients with CKD6,18–20. Consistent with the findings of previous studies, the multivariable analyses in our study showed that age (for AVC and MVC), systolic blood pressure (for AVC), coronary heart disease (for AVC and MVC), diabetes (for AVC and MVC), and Ca×P product (for AVC and MVC) and intact PTH levels (for AVC and MVC) were independently associated with cardiac valve calcification in patients with CKD.

The main finding of this study was that a low level of serum 1,25(OH)2D is independently associated with the presence of AVC and MVC in patients with CKD. Concerning the association between vitamin D deficiency and cardiac valve calcification, several studies have reported this association in patients with diseases other than CKD. Dishmon et al. showed that low levels of serum 25(OH)D are associated with cardiac valve calcification in patients with dilated cardiomyopathy without significant renal dysfunction25. Yusuf et al. reported that serum 25(OH)D levels correlated with the severity of valvular calcification in patients with rheumatic mitral stenosis26. Tibuakuu et al. reported a possible link between serum 25(OH)D level and the risk of incident mitral annulus calcification, but not AVC, in the general population free of preexisting clinical CVD10. To our knowledge, this is the first study to report an association between serum vitamin D deficiency (measured by serum 1,25(OH)2D levels) and cardiac valve calcification in patients with CKD.

Cistanche capsules

Our study demonstrated an independent association between serum 1,25(OH)2D and cardiac valve calcification even after adjustment for several confounding factors of CKD-MBD (calcium, phosphate, Ca×P product, and intact PTH levels), suggesting a direct causal role of low serum 1,25(OH)2D levels in cardiac valve calcification in patients with CKD. However, the pathophysiological explanation for the association between serum 1,25(OH)2D levels and cardiac valve calcification in patients with CKD is still unclear. One possible mechanism is that vitamin D may be involved in the differentiation of VICs into osteoblast-like cells. VICs are a major cellular component of cardiac valve leaflets. As valvular calcification progresses, a subpopulation of VICs undergoes a phenotypic transformation into osteoblast-like cells27. Osteoblast-like cells may be involved in the development of valvular calcification as osteoblasts play a central role in bone development27. Schmidt et al. showed that a low vitamin diet accelerated valvular calcification by differentiating VICs into osteoblast-like cells in an animal model, suggesting a causal role of vitamin D deficiency in valvular calcifcation28. In another report by Schmidt et al., vitamin D receptor (VDR) deficiency promoted AVC in a VDR−/− mouse model via upregulation of osteoblast transcription factors, which triggered the differentiation of VICs into osteoblast-like cells28. Another potential mechanism underlying the vitamin D–cardiac valve calcification association is inflammation. It is well established that inflammation promotes valvular calcifcation6,19. VDR is abundantly expressed in immune cells, and vitamin D has potent anti-inflammatory properties29. While physiological levels of vitamin D are capable of inhibiting calcification by modulating inflammation, vitamin D deficiency observed in patients with CKD leads to a pro-inflammatory activity that may subsequently drive calcifcation30.

However, the question remains whether vitamin D supplements can delay the progression of cardiac valve calcification in patients with CKD. About vascular calcification, the 2017 KDIGO guidelines on CKDMBD recommend avoiding calcitriol and vitamin D analog supplementation in patients with CKD not on dialysis because excessive vitamin D supplementation can cause hypercalcemia and hyperphosphatemia, which may promote vascular calcifcation31. If initiated for severe and progressive SHPT, calcitriol or vitamin D analogs should be started with low doses, and then titrated based on the PHT response. Thus, the 2017 KDIGO guidelines suggest that calcitriol and vitamin D analogs not be routinely used in patients with CKD, not on dialysis31. As to cardiac valve calcification, excessive vitamin D supplementation was shown to be associated with AVC in an animal model 32. Further clinical studies are needed to verify the effect of vitamin D supplementation on cardiac valve calcification in patients with CKD.

There were several limitations to the present study. First, owing to its retrospective and cross-sectional design, it was difficult to establish a temporal and causal relationship between serum 1,25(OH)2D levels and cardiac valve calcification. Further experimental and clinical studies are needed to establish the causal relationship between serum 1,25(OH)2D levels and cardiac valve calcification in patients with CKD. Second, our study was performed at a single center and had a relatively small sample size. Thus, our results may not be extrapolated to the overall population with CKD. Third, this study did not include fibroblast growth factor (FGF)23, which is one of the major components of CKD-MBD, in the analysis due to the retrospective design of this study. FGF23 is known to inhibit 1α-hydroxylase. Early in CKD, the decline in 1,25(OH)2D levels is likely due to the increase in FGF23 levels rather than the loss of functional renal mass33. Thus, if FGF23 levels had been included in the analysis, the association between serum 1,25(OH)2D and cardiac valve calcification could have been addressed in greater detail.

Nevertheless, the present study had several strengths. First, serum 1,25(OH)2D levels were measured instead of those of 25(OH)D. The levels of 1,25(OH)2D reflect the true biological activity of vitamin D because this form binds to VDR, whereas 25(OH)D levels reflect the vitamin D stores. After all, it is the main circulating form of vitamin D34. We think that the results of this study are more physiologically relevant than those of previous studies that measured 25(OH)D levels. Second, to unveil the association between vitamin D and cardiac valve calcification more clearly, we excluded the patients who were taking vitamin D supplements, calcimimetics, and phosphate binders, which could affect endogenous vitamin D metabolism. Third, we showed not only an independent association between serum 1,25(OH)2D levels and cardiac valve calcification but also the best cutoff values of serum 1,25(OH)2D levels to predict the presence of cardiac valve calcification, suggesting that serum 1,25(OH)2D levels may be a biomarker for cardiac valve calcification in patients with CKD.

Cistanche powder

In conclusion, our study demonstrates that serum 1,25(OH)2D level is independently associated with cardiac valve calcification and may be a potential biomarker for cardiac valve calcification in patients with CKD. Future studies are needed to demonstrate the role of vitamin D in the pathogenesis of cardiac valve calcification in CKD and to determine whether vitamin D therapy can prevent the progression of cardiac valve calcification in patients with CKD.

References

1. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351(13), 1296–1305 (2004).

2. Ix, J. H. et al. Kidney function and aortic valve and mitral annular calcification in the multi-ethnic study of atherosclerosis (MESA). Am. J. Kidney Dis. 50(3), 412–420 (2007).

3. Raggi, P. et al. All-cause mortality in hemodialysis patients with heart valve calcification. Clin. J. Am. Soc. Nephrol. 6(8), 1990–1995 (2011).

4. Wang, A. Y. et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J. Am. Soc. Nephrol. 14(1), 159–168 (2003).

5. Sharma, R. et al. Mitral annular calcification predicts mortality and coronary artery disease in end-stage renal disease. Atherosclerosis 191(2), 348–354 (2007).

6. Marwick, T. H. et al. Chronic kidney disease and valvular heart disease: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int. 96(4), 836–849 (2019).

7. Brahmbhatt, S., Mikhail, M., Islam, S. & Aloia, J. F. Vitamin D and abdominal aortic calcification in older African American women, the PODA clinical trial. Nutrients 12, 3 (2020).

8. Doherty, T. M. et al. Ethnic origin and serum levels of 1alpha, 25-dihydroxy vitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation 96(5), 1477–1481 (1997).

9. Watson, K. E. et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96(6), 1755–1760 (1997).

10. Tibuakuu, M. et al. Relation of serum vitamin D to the risk of mitral annular and aortic valve calcium (from the multi-ethnic study of atherosclerosis). Am. J. Cardiol. 120(3), 473–478 (2017).

11. Lim, K., Hamano, T. & Tadhani, R. Vitamin D and calcimimetics in cardiovascular disease. Semin. Nephrol. 38(3), 251–266 (2018).

12. de Boer, I. H. et al. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 20(8), 1805–1812 (2009).

13. Oh, K. H. et al. Te KNOW-CKD study: What we have learned about chronic kidney diseases. Kidney Res. Clin. Pract. 39(2), 121–135 (2020).

14. Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130(6), 461–470 (1999).

15. Kim, I. Y. et al. Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. PLoS ONE 16(5), e0251333 (2021).

16. Kim, I. Y. et al. Cardiac valve calcification is associated with the presence and severity of coronary artery disease in patients with predialysis chronic kidney disease. Clin. Exp. Nephrol. 19(6), 1090–1097 (2015).

17. Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28(1), 1–39 (2015).

18. Brandenburg, V. M., Schuh, A. & Kramann, R. Valvular calcification in chronic kidney disease. Adv. Chronic Kidney Dis. 26(6), 464–471 (2019).

19. Urena-Torres, P. et al. Valvular heart disease and calcification in CKD: More common than appreciated. Nephrol. Dial. Transplant. 35(12), 2046–2053 (2020).

20. Rong, S. et al. Risk factors for heart valve calcification in chronic kidney disease. Medicine (Baltimore) 97(5), e9804 (2018).

21. Jean, G., Souberbielle, J. C. & Chazot, C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients 9, 4 (2017).

22. Gembillo, G. et al. Protective role of vitamin D in renal tubulopathies. Metabolites 10, 3 (2020).

23. Gembillo, G., Siligato, R., Amatruda, M., Conti, G. & Santoro, D. Vitamin D, and Glomerulonephritis. Medicine (Kaunas) 57, 2 (2021).

24. Gembillo, G. et al. Role of vitamin D status in diabetic patients with renal disease. Medicina 55, 6 (2019).

25. Dishmon, D. A. et al. Hypovitaminosis D and valvular calcification in patients with dilated cardiomyopathy. Am. J. Med. Sci. 337(5), 312–316 (2009).

26. Yusuf, J., Mukhopadhyay, S., Vignesh, V. & Tyagi, S. Evaluation of serum 25-hydroxyvitamin D levels in calcific rheumatic mitral stenosis—A cross-sectional study. Indian Heart J. 70(2), 206–213 (2018).

27. Liu, A. C., Joag, V. R. & Gotlieb, A. I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171(5), 1407–1418 (2007).

28. Schmidt, N. et al. Vitamin D receptor deficiency and a low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS ONE 7(4), e35316 (2012).

29. Sallam, T., Tintut, Y. & Demer, L. L. Regulation of calcifc vascular and valvular disease by nuclear receptors. Curr. Opin. Lipidol. 30(5), 357–363 (2019).

30. Wang, J., Zhou, J. J., Robertson, G. R. & Lee, V. W. Vitamin D in vascular calcification: A double-edged sword?. Nutrients 10, 5 (2018).

31. Ketteler, M. et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 92(1), 26–36 (2017).

32. Drolet, M. C., Arsenault, M. & Couet, J. Experimental aortic valve stenosis in rabbits. J. Am. Coll. Cardiol. 41(7), 1211–1217 (2003).

33. Gutierrez, O. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16(7), 2205–2215 (2005).

34. Kim, I. Y. et al. A low 1,25-dihydroxy vitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Int. Urol. Nephrol. 50(12), 2255–2260 (2018).

IlYoung Kim1,2, Byung MinYe1,2, Min Jeong Kim1,2, Seo Rin Kim1,2, DongWon Lee1,2, Hyo Jin Kim1,3, Harin Rhee1,3, Sang Heon Song1,3, EunYoung Seong1,3 & Soo Bong Lee1,2

1 Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea.

2 Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea.

3 Medical Research Institute, Pusan National University Hospital, Busan, South Korea.